key: cord-0745761-9vvtiquw authors: Chen, Eunice C.; Miller, Steve A.; DeRisi, Joseph L.; Chiu, Charles Y. title: Using a Pan-Viral Microarray Assay (Virochip) to Screen Clinical Samples for Viral Pathogens date: 2011-04-27 journal: J Vis Exp DOI: 10.3791/2536 sha: 8198fbb4175a2f90bcb43dafc0a365677c916d77 doc_id: 745761 cord_uid: 9vvtiquw The diagnosis of viral causes of many infectious diseases is difficult due to the inherent sequence diversity of viruses as well as the ongoing emergence of novel viral pathogens, such as SARS coronavirus and 2009 pandemic H1N1 influenza virus, that are not detectable by traditional methods. To address these challenges, we have previously developed and validated a pan-viral microarray platform called the Virochip with the capacity to detect all known viruses as well as novel variants on the basis of conserved sequence homology(1). Using the Virochip, we have identified the full spectrum of viruses associated with respiratory infections, including cases of unexplained critical illness in hospitalized patients, with a sensitivity equivalent to or superior to conventional clinical testing(2-5). The Virochip has also been used to identify novel viruses, including the SARS coronavirus(6,7), a novel rhinovirus clade(5), XMRV (a retrovirus linked to prostate cancer)(8), avian bornavirus (the cause of a wasting disease in parrots)(9), and a novel cardiovirus in children with respiratory and diarrheal illness(10). The current version of the Virochip has been ported to an Agilent microarray platform and consists of ~36,000 probes derived from over ~1,500 viruses in GenBank as of December of 2009. Here we demonstrate the steps involved in processing a Virochip assay from start to finish (~24 hour turnaround time), including sample nucleic acid extraction, PCR amplification using random primers, fluorescent dye incorporation, and microarray hybridization, scanning, and analysis. . Using the Virochip, we have identified the full spectrum of viruses associated with respiratory infections, including cases of unexplained critical illness in hospitalized patients, with a sensitivity equivalent to or superior to conventional clinical testing [2] [3] [4] [5] . The Virochip has also been used to identify novel viruses, including the SARS coronavirus 6, 7 , a novel rhinovirus clade 5 , XMRV (a retrovirus linked to prostate cancer) 8 , avian bornavirus (the cause of a wasting disease in parrots) 9 , and a novel cardiovirus in children with respiratory and diarrheal illness 10 . The current version of the Virochip has been ported to an Agilent microarray platform and consists of ~36,000 probes derived from over ~1,500 viruses in GenBank as of December of 2009. Here we demonstrate the steps involved in processing a Virochip assay from start to finish (~24 hour turnaround time), including sample nucleic acid extraction, PCR amplification using random primers, fluorescent dye incorporation, and microarray hybridization, scanning, and analysis. The video component of this article can be found at http://www.jove.com/video/2536/ The steps of the Virochip assay include (1) nucleic acid extraction from clinical samples, (2) reverse transcription of extracted RNA and 2 nd strand cDNA synthesis, (3) PCR amplification of randomly primed cDNA, (3) Cy3 fluorescent dye incorporation, (4) hybridization of labeled material to the Virochip microarray, and (5) scanning and analysis ( Figure 1 ). The protocol shown below will demonstrate the use of the Virochip assay on a nasal swab sample from a child with an influenza-like illness. Primer A 5'-GTTTCCCAGTCACGATA-(N 9 )-3' Primer B 5'-GTTTCCCAGTCACGATA-3' Add 5 uL of Rd A sample to 45 μL of a master mix consisting of 5 μL 10X PCR buffer, 1 μL 12.5 mM dNTP, 1 μL 100 pmol / μL primer B, 1 μL KlenTaq LA (Sigma), and 37 μL water Run PCR protocol as follows: 94°C, 2 min →(25 cycles of 94°C, 30 s / 50°C, 45 s / 72°C, 1 min) →72°C, 5 min Check the Rd B sample on a 1.5% agarose electrophoresis gel. A smear from approximately 200 -1000 bp should be visualized Optional : another sample can be labeled with the Cy5 fluorescent dye and hybridized to the same microarray. 2. To incorporate aa-dNTP, add 5 uL of Rd B sample to 45 uL of a master mix consisting of 5 uL 10X PCR buffer, 1 uL 12.5 mM aa-dNTP(Invitrogen), 1 uL 100 pmol / uL primer B, 1, 1 uL KlenTaq LA (Sigma), and 37 uL water. Run PCR protocol as follows: 94°C, 2 min →(15cycles of 94°C Clean the Rd C sample with the DNA Clean and Concentrator-5 Kit (Zymo Research) per the manufacturer's instructions Add 1 uL of 1M bicarbonate (Sigma) and 1 uL Cy5 (GE Healthcare) to the Rd C sample Incubate x 1 hour in the dark Clean the Cy3-labeled sample with the DNA Clean and Concentrator-5 Kit (Zymo Research) per the manufacturer's instructions Optional: use 1.5 μL to check cDNA concentration and the amount of dye incorporated on a Nanodrop spectrophotometer 5 μL (or amount to normalize) of Cy3-labeled sample Add 25 μL of 2X GEx hybridization buffer (Agilent) San Francisco / Agilent) (side marked "Agilent" down) on top of gasket slide and fasten screw tightly Hybridize overnight in 65°C oven, speed setting at 10 rpm Wash in buffer 1 x 1 min. Wash in preheated buffer 2 x 1 min. Slowly remove slide from buffer 2, being careful to avoid bubbles Virochip Scanning and Analysis 1. Scan Cy3-labeled array at 5 μm or 2 μm according to the instrument's standard scanning protocol (Figure 2B) Analyze Virochip microarrays by visual inspection, cluster analysis, or the automated Virochip analysis program, E-Predict 11 . By each of these three methods, influenza virus is readily detected in the nasal swab sample Microarray-based detection and genotyping of viral pathogens Diagnosis of a critical respiratory illness caused by human metapneumovirus by use of a pan-virus microarray Microarray detection of human parainfluenzavirus 4 infection associated with respiratory failure in an immunocompetent adult Utility of DNA microarrays for detection of viruses in acute respiratory tract infections in children Pan-viral screening of respiratory tract infections in adults with and without asthma reveals unexpected human coronavirus and human rhinovirus diversity Characterization of a novel coronavirus associated with severe acute respiratory syndrome Viral discovery and sequence recovery using DNA microarrays Identification of a novel Gammaretrovirus in prostate tumors of patients homozygous for R462Q RNASEL variant Recovery of divergent avian bornaviruses from cases of proventricular dilatation disease: identification of a candidate etiologic agent Identification of cardioviruses related to Theiler's murine encephalomyelitis virus in human infections E-Predict: a computational strategy for species identification based on observed DNA microarray hybridization patterns We thank David Wang, Anatoly Urisman, Amy Kistler, Kael Fischer, Patrick Tang, and Alexander Greninger for the initial development and optimization of the Virochip protocol. This work is supported by an NIH K08 grant and Abbott Discovery Award (to CC) and the Howard Hughes Medical Institute (to JLD).